Male and females aged between 18 and 65 years of age inclusive, at the time of signing the informed consent. 
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. 
Body weight >= 50 kilogram (kg) and body mass index within the range 19 - 24.9 kg/m^2 (inclusive). 
A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use one of the contraception methods listed in protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up contact visit; OR has only same-sex partners, when this is her preferred and usual lifestyle. 
Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up contact visit. 
Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form 
Alanine aminotransferase, alkaline phosphatase and bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). 
Based on single or averaged corrected QT interval (QTc) values of triplicate electrocardiograms obtained over a brief recording period: QTcF < 450 msec 

NCT02201316_inc_T1
Person
Male
NCT02201316_inc_T2
Person
females
NCT02201316_inc_T4
Person
aged
NCT02201316_inc_T5
Value
between 18 and 65 years
NCT02201316_inc_T6
Person
age
NCT02201316_inc_T7
Temporal
at the time of signing the informed consent
NCT02201316_inc_T8
Reference_point
signing the informed consent
NCT02201316_inc_T9
Condition
Healthy
NCT02201316_inc_T10
Qualifier
as determined by a responsible and experienced physician
NCT02201316_inc_T13
Procedure
medical evaluation
NCT02201316_inc_T14
Observation
medical history
NCT02201316_inc_T15
Procedure
physical examination
NCT02201316_inc_T16
Procedure
laboratory tests
NCT02201316_inc_T17
Procedure
cardiac monitoring
NCT02201316_inc_T18
Condition
clinical abnormality
NCT02201316_inc_T20
Value
outside the reference range
NCT02201316_inc_T21
Measurement
laboratory parameter
NCT02201316_inc_T26
Measurement
Body weight
NCT02201316_inc_T27
Value
>= 50 kilogram (kg)
NCT02201316_inc_T28
Measurement
body mass index
NCT02201316_inc_T29
Value
within the range 19 - 24.9 kg/m^2
NCT02201316_inc_T30
Condition
childbearing potential
NCT02201316_inc_T31
Negation
Non
NCT02201316_inc_T32
Condition
pre-menopausal
NCT02201316_inc_T33
Person
females
NCT02201316_inc_T34
Person
female
NCT02201316_inc_T35
Procedure
tubal ligation
NCT02201316_inc_T36
Procedure
hysterectomy
NCT02201316_inc_T37
Condition
postmenopausal
NCT02201316_inc_T38
Temporal
12 months
NCT02201316_inc_T39
Condition
spontaneous amenorrhea
NCT02201316_inc_T40
Measurement
follicle stimulating hormone (FSH)
NCT02201316_inc_T41
Value
> 40 milli-international units per milliliter (MlU/mL)
NCT02201316_inc_T42
Measurement
estradiol
NCT02201316_inc_T43
Value
< 40 picograms per mililiter (pg/mL)
NCT02201316_inc_T44
Value
<147 picomole per liter
NCT02201316_inc_T45
Scope
follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter
NCT02201316_inc_T46
Scope
pre-menopausal females with a documented tubal ligation or hysterectomy
NCT02201316_inc_T47
Scope
pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-international units per milliliter (MlU/mL) and estradiol < 40 picograms per mililiter (pg/mL) [<147 picomole per liter] is confirmatory]
NCT02201316_inc_T48
Procedure
hormone replacement therapy (HRT)
NCT02201316_inc_T49
Person
Females
NCT02201316_inc_T50
Measurement
menopausal status
NCT02201316_inc_T51
Value
in doubt
NCT02201316_inc_T68
Measurement
Alanine aminotransferase
NCT02201316_inc_T69
Measurement
alkaline phosphatase
NCT02201316_inc_T70
Measurement
bilirubin
NCT02201316_inc_T71
Scope
Alanine aminotransferase, alkaline phosphatase and bilirubin
NCT02201316_inc_T72
Value
<=1.5x upper limit of normal (ULN)
NCT02201316_inc_T73
Measurement
bilirubin
NCT02201316_inc_T74
Value
>1.5xULN
NCT02201316_inc_T75
Measurement
direct bilirubin
NCT02201316_inc_T77
Measurement
QTcF
NCT02201316_inc_T78
Value
< 450 msec
NCT02201316_inc_T79
Qualifier
single
NCT02201316_inc_T80
Qualifier
averaged
NCT02201316_inc_T81
Scope
single or averaged
NCT02201316_inc_T82
Measurement
corrected QT interval (QTc)
NCT02201316_inc_T83
Procedure
electrocardiograms
NCT02201316_inc_T84
Temporal
over a brief recording period